Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1α/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice

Sorafenib—a broad kinase inhibitor—is a standard therapy for advanced hepatocellular carcinoma (HCC), and has been shown to exert anti-fibrotic effects in liver cirrhosis, a precursor of HCC. However, the effects of sorafenib on tumor desmoplasia—and its consequences on treatment resistance — remain...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chen, Yunching, Huang, Yuhui, Reiberger, Thomas, Duyverman, Annique M., Huang, Peigen, Samuel, Rekha, Hiddingh, Lotte, Roberge, Sylvie, Koppel, Christina, Lauwers, Gregory Y., Zhu, Andrew X., Jain, Rakesh K., Duda, Dan G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3966948/
https://ncbi.nlm.nih.gov/pubmed/24242874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.26790
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados